Literature DB >> 31326077

Effect of Diabetes Mellitus on Cardiac Resynchronization Therapy and to Prognosis in Heart Failure (from the Prospective Evaluation of Asian With Cardiac Resynchronization Therapy for Heart Failure Study).

Eugene S J Tan1, Joevy Lim2, Siew Pang Chan3, Joshua Tze-Kiat Seow4, Devinder Singh5, Wee Tiong Yeo5, Toon Wei Lim5, Pipin Kojodjojo5, Swee-Chong Seow5.   

Abstract

The association of diabetes mellitus (DM) with cardiac resynchronization therapy (CRT) response and cardiovascular outcomes in Asian patients with heart failure (HF) is unclear. This study aims to investigate the effects of DM on CRT response and cardiovascular outcomes in Asian HF patients. Consecutive Asian HF patients receiving CRT were enrolled in the Prospective Evaluation of Asian with CRT for Heart Failure (PEACH) study from 2011 to 2017. CRT response and super-response were defined as decrease in end-systolic volume index ≥15% and ≥30%, respectively. Primary endpoint was time to composite of HF-hospitalization and all-cause mortality. Among 161 patients followed for 3.3 ± 1.5 years (age 66.7 ± 11.2 years, 22% females, mean QRS duration 154.3 ± 22.4 ms, 83% left bundle branch block), 84 (52%) were CRT responders and 57 (35%) were super-responders. Of 82 (51%) patients with DM (100% type 2, mean HbA1c 7.3 ± 1.9%), 35 (43%) were responders. DM attenuated reverse remodeling (CRT response: AOR 0.44, 95% confidence interval [CI] 0.20 to 0.98, p < 0.05; super-response: AOR 0.42, 95% CI 0.18 to 0.97, p <0.05), and DM increased HF-hospitalization and all-cause mortality (AHR 1.68, 95% CI 1.00 to 2.82, p = 0.05). The extent of CRT-response correlates with higher event-free survival (CRT response: AHR 0.5, 95% CI 0.30 to 0.81, p = 0.005; super-response: AHR 0.27, 95% CI 0.14 to 0.52, p < 0.001). In conclusion, the extent of reverse remodeling post-CRT is the strongest predictor of event free survival. However, DM is detrimental to the CRT recipient by attenuating reverse remodeling, inducing end organ dysfunction and is independently associated with worsened clinical outcomes among Asian HF patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31326077     DOI: 10.1016/j.amjcard.2019.06.004

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Clinical and gated SPECT MPI parameters associated with super-response to cardiac resynchronization therapy.

Authors:  Claudio T Mesquita; Amalia Peix; Fernando de Amorim Fernandes; Raffaele Giubbini; Ganesan Karthikeyan; Teresa Massardo; Chetan Patel; Luz M Pabon; Amelia Jimenez-Heffernan; Erick Alexanderson; Sadaf Butt; Alka Kumar; Victor Marin; Olga Morozova; Diana Paez; Ernest V Garcia
Journal:  J Nucl Cardiol       Date:  2020-11-05       Impact factor: 3.872

2.  Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a long-term retrospective cohort study.

Authors:  Peter C Kahr; Sander Trenson; Matthias Schindler; Joël Kuster; Philippe Kaufmann; Johanna Tonko; Daniel Hofer; Devdas T Inderbitzin; Alexander Breitenstein; Ardan M Saguner; Andreas J Flammer; Frank Ruschitzka; Jan Steffel; Stephan Winnik
Journal:  ESC Heart Fail       Date:  2020-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.